Open Access

REVIEW

Aberrant lncRNA Expression in Multiple Myeloma

by

* Department of Medical Laboratory, Wuhan General Hospital of PLA, Wuhan, P.R. China
† Discipline Section of Medical Department, Wuhan General Hospital of PLA, Wuhan, P.R. China
1 These authors provided equal contribution to this work.

Oncology Research 2018, 26(5), 809-816. https://doi.org/10.3727/096504017X15123872205507

Abstract

Multiple myeloma (MM), a type of malignant tumor, is characterized by dysplasia of clonal plasma cells in the bone marrow. People with MM will have damaged organs or tissues due to secretion of large amounts of monoclonal immunoglobulin or fragments (M protein). Despite improved survivability by novel treatment strategies over the last decade, MM is still incurable by current therapies. Long noncoding RNAs (lncRNAs), with length of more than 200 nucleotides, have been reported to act as important regulators in many diseases, including MM. Recent studies have reported aberrant lncRNA expression in MM; these dysregulated lncRNAs can play oncogenic and/or tumor-suppressive roles in the development and progression of MM. In this article, we present a general overview on the role of lncRNAs in MM pathogenesis and discuss their potential as prognostic biomarkers and targets for treatment.

---

Keywords

---